Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.53 |
| ▸ | OPRK1 | P41145 | 6/20 | 0.49 |
| ▸ | STAT3 | P40763 | 1/20 | 0.47 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 2/20 | 0.47 |
| ▸ | ADRB3 | P13945 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6680379 | 0.91 | KMT2A (0.47) | KMT2AMEN1NOD2OPRK1STAT3 | |
| SCHEMBL6663218 | 0.82 | KMT2A (0.52) | KMT2AMEN1NOD2STAT3ADRB2 | |
| SCHEMBL6836276 | 0.81 | ADRB2 (0.60) | KMT2AMEN1ADRB2ADRB1ADRB3 | |
| SCHEMBL6838303 | 0.79 | MEN1 (0.66) | KMT2AMEN1NOD2STAT3ALDH1A1 | |
| SCHEMBL2369149 | 0.78 | MEN1 (0.71) | KMT2AMEN1NOD2STAT3ALDH1A1 | |
| SCHEMBL6836284 | 0.76 | KMT2A (0.56) | KMT2AMEN1NOD2STAT3ADRB2 | |
| SCHEMBL6678332 | 0.76 | LMNA (0.53) | KMT2AMEN1OPRK1ADRB2ADRB1 | |
| SCHEMBL6665434 | 0.74 | MEN1 (0.53) | KMT2AMEN1NOD2STAT3ADRB2 | |
| SCHEMBL6838294 | 0.73 | MEN1 (0.67) | KMT2AMEN1NOD2STAT3ALDH1A1 | |
| SCHEMBL6663592 | 0.72 | ADRB2 (0.50) | KMT2AADRB2ADRB1ADRB3HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | claimed |
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | claimed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | claimed |
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | PREDIX PHARMACEUTICALS HOLDINGS, INC. | 2004-07-15 | — | — | US | claimed |
| WO-2004014850-A2 | SUBSTITUTED AMINOPYRIMIDINES AS NEUROKININ ANTAGONISTS | PREDIX PHARMACEUTICALS HOLDINGS, INC. (US) | 2004-02-19 | — | — | WO | claimed |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LTD (GB) | 2016-06-02 | — | — | US | disclosed |
| US-9290511-B2 | Thieno-pyrimidines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2016-03-22 | — | — | US | disclosed |
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | XENTION LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| EP-2780343-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | Xention Limited (GB) | 2014-09-24 | — | — | EP | disclosed |
| WO-2013072694-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | XENTION LIMITED (GB) | 2013-05-23 | — | — | WO | disclosed |
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | PREDIX PHARMACEUTICALS HOLDINGS, INC. | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371203-A1 | Thieno- and furo - pyrimidines and pyridines, useful as potassium channel inhibitors | KCNA3, KCNJ1, KCNJ11 | KMT2A 1039/4885MEN1 1141/4885NOD2 2062/4885 |
| US-20160152634-A1 | THIENO- AND FURO - PYRIMIDINES AND PYRIDINES, USEFUL AS POTASSIUM CHANNEL INHIBITORS | KCNA3, KCNJ1, KCNJ11 | KMT2A 1025/4885MEN1 1205/4885NOD2 1923/4885 |
| US-20040138238-A1 | Substituted aminopyrimidine compounds as neurokinin antagonists | TACR1, GRPR, BDKRB1 | KMT2A 3337/4885MEN1 2034/4885NOD2 504/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.